A multitarget basal ganglia dopaminergic and GABAergic transplantation strategy enhances behavioural recovery in parkinsonian rats

K. Mukhida, M. Hong, G. B. Miles, Timothy James Phillips, B. A. Baghbaderani, M. McLeod, N. Kobayashi, A. Sen, L. A. Behie, R. M. Brownstone, I. Mendez

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

The current transplantation paradigm for Parkinson's disease that places foetal dopaminergic cells in the striatum neither normalizes neuronal activity in basal ganglia structures such as the substantia nigra (SN) and subthalamic nucleus (STN) nor leads to complete functional recovery. It was hypothesized that restoration of parkinsonian deficits requires inhibition of the pathological overactivity of the STN and SN in addition to restoration of dopaminergic activity in the striatum. To achieve inhibition, a multitargeted basal ganglia transplantation strategy using GABAergic cells derived from either foetal striatal primordia (FSP) cells or human neural precursor cells (hNPCs) expanded in suspension bioreactors was investigated. In hemiparkinsonian rats, transplantation of foetal rat dopaminergic cells in the striatum in conjunction with GABAergic grafts in the STN and/or SN promoted significant improvement in forelimb akinesia and motor function compared to transplantation of intrastriatal dopaminergic grafts alone or in conjunction with undifferentiated hNPCs. In culture, FSP cells exhibited neuronal electrophysiological properties. However, recordings from GABAergic hNPCs revealed limited ionic conductances and an inability to fire action potentials. Despite this, they were almost as efficacious as FSP cells in inducing functional recovery following transplantation, suggesting that such recovery may have been mediated by secretion of GABA rather than by functional integration into the host. Thus, restoration of dopaminergic activity to the striatum in concert with inhibition of the STN and SN by GABAergic grafts may be beneficial for improving clinical outcomes in patients with Parkinson's disease and potential clinical application of this strategy may be enhanced by the use of differentiated hNPCs.

Original languageEnglish (US)
Pages (from-to)2106-2126
Number of pages21
JournalBrain
Volume131
Issue number8
DOIs
StatePublished - Aug 1 2008
Externally publishedYes

Fingerprint

Basal Ganglia
Transplantation
Subthalamic Nucleus
Substantia Nigra
Corpus Striatum
Transplants
Parkinson Disease
Forelimb
Bioreactors
gamma-Aminobutyric Acid
Action Potentials
Suspensions

Keywords

  • GABA
  • Parkinson's disease
  • Subthalamic nucleus
  • Transplantation

ASJC Scopus subject areas

  • Clinical Neurology

Cite this

Mukhida, K., Hong, M., Miles, G. B., Phillips, T. J., Baghbaderani, B. A., McLeod, M., ... Mendez, I. (2008). A multitarget basal ganglia dopaminergic and GABAergic transplantation strategy enhances behavioural recovery in parkinsonian rats. Brain, 131(8), 2106-2126. https://doi.org/10.1093/brain/awn149

A multitarget basal ganglia dopaminergic and GABAergic transplantation strategy enhances behavioural recovery in parkinsonian rats. / Mukhida, K.; Hong, M.; Miles, G. B.; Phillips, Timothy James; Baghbaderani, B. A.; McLeod, M.; Kobayashi, N.; Sen, A.; Behie, L. A.; Brownstone, R. M.; Mendez, I.

In: Brain, Vol. 131, No. 8, 01.08.2008, p. 2106-2126.

Research output: Contribution to journalArticle

Mukhida, K, Hong, M, Miles, GB, Phillips, TJ, Baghbaderani, BA, McLeod, M, Kobayashi, N, Sen, A, Behie, LA, Brownstone, RM & Mendez, I 2008, 'A multitarget basal ganglia dopaminergic and GABAergic transplantation strategy enhances behavioural recovery in parkinsonian rats', Brain, vol. 131, no. 8, pp. 2106-2126. https://doi.org/10.1093/brain/awn149
Mukhida, K. ; Hong, M. ; Miles, G. B. ; Phillips, Timothy James ; Baghbaderani, B. A. ; McLeod, M. ; Kobayashi, N. ; Sen, A. ; Behie, L. A. ; Brownstone, R. M. ; Mendez, I. / A multitarget basal ganglia dopaminergic and GABAergic transplantation strategy enhances behavioural recovery in parkinsonian rats. In: Brain. 2008 ; Vol. 131, No. 8. pp. 2106-2126.
@article{214cd7f60ffa498694c7df64c87f9271,
title = "A multitarget basal ganglia dopaminergic and GABAergic transplantation strategy enhances behavioural recovery in parkinsonian rats",
abstract = "The current transplantation paradigm for Parkinson's disease that places foetal dopaminergic cells in the striatum neither normalizes neuronal activity in basal ganglia structures such as the substantia nigra (SN) and subthalamic nucleus (STN) nor leads to complete functional recovery. It was hypothesized that restoration of parkinsonian deficits requires inhibition of the pathological overactivity of the STN and SN in addition to restoration of dopaminergic activity in the striatum. To achieve inhibition, a multitargeted basal ganglia transplantation strategy using GABAergic cells derived from either foetal striatal primordia (FSP) cells or human neural precursor cells (hNPCs) expanded in suspension bioreactors was investigated. In hemiparkinsonian rats, transplantation of foetal rat dopaminergic cells in the striatum in conjunction with GABAergic grafts in the STN and/or SN promoted significant improvement in forelimb akinesia and motor function compared to transplantation of intrastriatal dopaminergic grafts alone or in conjunction with undifferentiated hNPCs. In culture, FSP cells exhibited neuronal electrophysiological properties. However, recordings from GABAergic hNPCs revealed limited ionic conductances and an inability to fire action potentials. Despite this, they were almost as efficacious as FSP cells in inducing functional recovery following transplantation, suggesting that such recovery may have been mediated by secretion of GABA rather than by functional integration into the host. Thus, restoration of dopaminergic activity to the striatum in concert with inhibition of the STN and SN by GABAergic grafts may be beneficial for improving clinical outcomes in patients with Parkinson's disease and potential clinical application of this strategy may be enhanced by the use of differentiated hNPCs.",
keywords = "GABA, Parkinson's disease, Subthalamic nucleus, Transplantation",
author = "K. Mukhida and M. Hong and Miles, {G. B.} and Phillips, {Timothy James} and Baghbaderani, {B. A.} and M. McLeod and N. Kobayashi and A. Sen and Behie, {L. A.} and Brownstone, {R. M.} and I. Mendez",
year = "2008",
month = "8",
day = "1",
doi = "10.1093/brain/awn149",
language = "English (US)",
volume = "131",
pages = "2106--2126",
journal = "Brain",
issn = "0006-8950",
publisher = "Oxford University Press",
number = "8",

}

TY - JOUR

T1 - A multitarget basal ganglia dopaminergic and GABAergic transplantation strategy enhances behavioural recovery in parkinsonian rats

AU - Mukhida, K.

AU - Hong, M.

AU - Miles, G. B.

AU - Phillips, Timothy James

AU - Baghbaderani, B. A.

AU - McLeod, M.

AU - Kobayashi, N.

AU - Sen, A.

AU - Behie, L. A.

AU - Brownstone, R. M.

AU - Mendez, I.

PY - 2008/8/1

Y1 - 2008/8/1

N2 - The current transplantation paradigm for Parkinson's disease that places foetal dopaminergic cells in the striatum neither normalizes neuronal activity in basal ganglia structures such as the substantia nigra (SN) and subthalamic nucleus (STN) nor leads to complete functional recovery. It was hypothesized that restoration of parkinsonian deficits requires inhibition of the pathological overactivity of the STN and SN in addition to restoration of dopaminergic activity in the striatum. To achieve inhibition, a multitargeted basal ganglia transplantation strategy using GABAergic cells derived from either foetal striatal primordia (FSP) cells or human neural precursor cells (hNPCs) expanded in suspension bioreactors was investigated. In hemiparkinsonian rats, transplantation of foetal rat dopaminergic cells in the striatum in conjunction with GABAergic grafts in the STN and/or SN promoted significant improvement in forelimb akinesia and motor function compared to transplantation of intrastriatal dopaminergic grafts alone or in conjunction with undifferentiated hNPCs. In culture, FSP cells exhibited neuronal electrophysiological properties. However, recordings from GABAergic hNPCs revealed limited ionic conductances and an inability to fire action potentials. Despite this, they were almost as efficacious as FSP cells in inducing functional recovery following transplantation, suggesting that such recovery may have been mediated by secretion of GABA rather than by functional integration into the host. Thus, restoration of dopaminergic activity to the striatum in concert with inhibition of the STN and SN by GABAergic grafts may be beneficial for improving clinical outcomes in patients with Parkinson's disease and potential clinical application of this strategy may be enhanced by the use of differentiated hNPCs.

AB - The current transplantation paradigm for Parkinson's disease that places foetal dopaminergic cells in the striatum neither normalizes neuronal activity in basal ganglia structures such as the substantia nigra (SN) and subthalamic nucleus (STN) nor leads to complete functional recovery. It was hypothesized that restoration of parkinsonian deficits requires inhibition of the pathological overactivity of the STN and SN in addition to restoration of dopaminergic activity in the striatum. To achieve inhibition, a multitargeted basal ganglia transplantation strategy using GABAergic cells derived from either foetal striatal primordia (FSP) cells or human neural precursor cells (hNPCs) expanded in suspension bioreactors was investigated. In hemiparkinsonian rats, transplantation of foetal rat dopaminergic cells in the striatum in conjunction with GABAergic grafts in the STN and/or SN promoted significant improvement in forelimb akinesia and motor function compared to transplantation of intrastriatal dopaminergic grafts alone or in conjunction with undifferentiated hNPCs. In culture, FSP cells exhibited neuronal electrophysiological properties. However, recordings from GABAergic hNPCs revealed limited ionic conductances and an inability to fire action potentials. Despite this, they were almost as efficacious as FSP cells in inducing functional recovery following transplantation, suggesting that such recovery may have been mediated by secretion of GABA rather than by functional integration into the host. Thus, restoration of dopaminergic activity to the striatum in concert with inhibition of the STN and SN by GABAergic grafts may be beneficial for improving clinical outcomes in patients with Parkinson's disease and potential clinical application of this strategy may be enhanced by the use of differentiated hNPCs.

KW - GABA

KW - Parkinson's disease

KW - Subthalamic nucleus

KW - Transplantation

UR - http://www.scopus.com/inward/record.url?scp=49449094466&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=49449094466&partnerID=8YFLogxK

U2 - 10.1093/brain/awn149

DO - 10.1093/brain/awn149

M3 - Article

C2 - 18669492

AN - SCOPUS:49449094466

VL - 131

SP - 2106

EP - 2126

JO - Brain

JF - Brain

SN - 0006-8950

IS - 8

ER -